Skye Bioscience, Inc.SKYENASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank0
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-43.06M
↓ 246% vs avg
Percentile
P0
Near historical low
Streak
8 yr
Consecutive declineContracting
Average
$-12.43M
Historical baseline
PeriodValueYoY Change
2025$-43.06M-70.6%
2024$-25.24M-80.9%
2023$-13.95M-9.5%
2022$-12.74M-96.8%
2021$-6.47M-6.9%
2020$-6.05M-0.4%
2019$-6.03M-52.9%
2018$-3.94M-19.6%
2017$-3.30M+7.2%
2016$-3.55M-